Management

Graham Kelly - Managing Director and Chief Executive Officer

Graham graduated with degrees in Science (1968) and Veterinary Science (1969) from The University of Sydney. After graduation he joined the newly-formed Department of Transplant Surgery in the Faculty of Medicine at The University of Sydney, gaining a Doctor of Philosophy in 1972. The subject of his PhD thesis was the manufacture and use of a novel drug for the treatment of tissue rejection in kidney transplant recipients, with that drug subsequently being commercialised and used globally in kidney transplantation. Graham was appointed Senior Research Fellow in Experimental Surgery at The University of Sydney, contributing through research in the areas of organ recovery for transplantation and liver transplant surgery. The increased susceptibility of organ transplant recipients to malignant cancer eventually led Graham to focus on the causes of that phenomenon, and in turn, to the broader issue of the link between diet and the incidences of certain cancers. The latter area of research led to a research interest in dietary isoflavones and their role in human health.

Graham developed a theory that dietary isoflavones were metabolised within the body into novel chemicals that possessed important hormone-like functions, and as such made important contributions to human health. That theory provided the basis for Graham leaving academia and founding the company, Norvet Ltd, which listed on the ASX in 1994. That company subsequently changed its name to Novogen Ltd and listed in the US on NASDAQ (1998). Graham was variously CEO, Executive Chairman and an Executive Director of Novogen, 1994-2006. He also was Executive Chairman of Marshall Edwards Inc (MEI) which listed on London’s AIM exchange (2001) and NASDAQ (2003). MEI subsequently became MEI Pharma Inc. Graham resigned from his executive and Board positions at Novogen and MEI in 2006.

In 2011, Graham joined private biotechnology company, Triaxial Pharmaceuticals Pty Ltd, as Executive Chairman. Concerned at the direction being taken by the Novogen Board in having stripped all assets from the Company and leaving it without a business, Graham engineered a reverse takeover of Novogen Ltd by Triaxial in December 2012 and set about rebuilding the Company. He remained as CEO and Executive Chairman of Novogen until June 2015 and was responsible for in-licensing that Company’s anti-tropomyosin drug technology, for establishing a joint venture company with Yale University, and for establishing a solid financial base.

In early-2012, Graham addressed the matter of the transport of isoflavones in the blood of humans, conducting formulation studies in a private capacity that led shortly thereafter to the concept behind NOX66. After leaving Novogen in 2015, Graham established private biotechnology company Noxopharm Pty Ltd in order to commercialise NOX66.


Greg van Wyk

Dr Greg van Wyk – Chief Medical Officer

Greg graduated as a medical doctor, from the University of the Witwatersrand, in 2001 and worked clinically, in hospitals and in GP practice, for 5 years prior to moving into pharmaceutical medicine. Over the past 12 years, he has led large, diverse medical teams across Australasia and North-western Europe and has worked across a range of therapeutic areas, on medicines in all stages of the product Lifecyle.

In both clinical and commercial contexts, Greg is a strategic thinker who is focused on achieving valued outcomes for the multitude of stakeholders engaged with the pharmaceutical industry. He enjoys research design and analysis and he enjoys continuous learning. 

Greg has postgraduate degrees in management and economics and is currently doing a Master of Data Science degree at the University of Sydney. He is passionate about the healthcare economy and the role of technology in extending and enhancing people’s lives.


John Wilkinson

Dr John Wilkinson - Chief Scientific Officer

John brings over 30 years of experience from both pharmaceutical and research settings in Australia and the United Kingdom, with a focus on the development of small molecules to target viruses and cancer.  John graduated from the University of Portsmouth (BSc Hons) in 1988 and has a PhD in HIV-1 Immunovirology from the University of NSW.  His research interests include Drug Development, Virology, Oncology and Immunology, translating novel laboratory findings into human clinical trials that have previously resulted in numerous peer-reviewed publications.  Prior to joining Noxopharm, John was the Chief Scientific Officer at Biotron Limited, where he was responsible for the oversight of Biotron's antiviral programs and instrumental in the HIV-1 clinical programs.  At Noxopharm, John will manage the scientific, research and technological operations of the company, help set company research and scientific priorities that align with the company's mission and vision.


Ron Sinani

Ron Sinani – Director, Regulatory Affairs

Ron Sinani practised as an oncology pharmacist prior to joining the pharmaceutical industry in 1992. Although his primary focus has been regulatory affairs, he has held roles involving medical affairs, pharmacovigilance, clinical research, quality assurance and health economics. Ron worked for a number of multinationals, including Sandoz (now Novartis), Abbott and Lundbeck before joining Pharmaxis in 2004 to establish its regulatory affairs capabilities and achieving marketing approval of its first product, Aridol® (in vivo diagnostic for asthma) in Australia and a number of global markets. He was also the regulatory lead for the company’s second product, Bronchitol® for the treatment of the orphan disease, cystic fibrosis. These global projects have provided Ron direct experience with overseas regulatory agencies in the US, Canada, Europe and Asia; as well as Australia. More recently, he was a regulatory strategist at Shire Pharmaceuticals where he gained insight into assessment of licensing opportunities and intellectual property protection. Ron has also consulted for the industry, first for Covance and then his own consultancy before joining Noxopharm in 2017.


Lara Babich

Dr Lara Babich - Director, Manufacturing

Born and raised in Trieste (Italy), Lara studied at the University of Padua (Italy), where she received a BSc in Biotechnology and a MSc in Industrial Biotechnology.
She then moved to the Netherlands, where she completed in 2013 a PhD in (bio)Chemistry at the University of Amsterdam working on engineered enzymes to perform chemical processes for the synthesis of pharmaceutical scaffolds.

In 2013, Lara joined Janssen Infectious Diseases and Vaccines (a Johnson&Johnson Company) in Leiden, the Netherlands, as Drug Product Formulation Development scientist working on several  investigational vaccines against infectious diseases like Ebola, HIV, RSV, Polio, etc...  In this role at the interface between R&D and GMP manufacturing, she worked on the development and implementation of liquid sterile formulations for injectable vaccines (biologics). Being part of the Chemistry, Manufacturing and Control (CMC team), Lara worked in several cross-functional and cross-site teams coordinating the path towards the start of each clinical phase.

After relocating to Australia, Lara joined Noxopharm in January 2018 as Director of Manufacturing, where she coordinates NOX66 process development, manufacturing, quality control and testing.


Frederic Delebecque

Dr Frederic Delebecque – Director, Pre-Clinical Oncology

Frederic has a PhD in Virology from the University Pierre and Marie Curie in Paris, France, achieved at the Pasteur Institute. Following his PhD, he performed his postdoctoral training at the Pasteur Institute and at the prestigious University of California, Berkeley. He also has a degree in chemical engineering from the National Engineer School of Chemistry in Montpellier, France. In addition to his academic training, Frederic has extensive experience in Research and Development and Quality Assurance at leading pharmaceutical and biotech companies, including pre-clinical, clinical and medical research spanning several disease areas.

In 2009, Frederic joined Novartis Pharma AG in Basel, Switzerland as a Principal Scientist in the Laboratory of Cell line and Adventitious agents Analytics. He was involved in multiple cross-functional projects within Regulatory Chemistry, Manufacturing and Controls and oversaw the adventitious agents testing of production cell banks for biologicals generating regulatory documents for submission to health authorities (FDA, Swissmedic and EMA).

In 2011, Frederic moved to Australia and joined Calimmune, a clinical-stage multinational biotech company, as a Senior Scientist to supervise their pre-clinical work. After approval to conduct a Phase I/II clinical trial in the USA to test a unique stem-cell based gene therapy against HIV, Frederic moved to a Quality Assurance Director position in 2013. In this role, he was responsible for all Quality Assurance, including the development, implementation and maintenance of the Quality Management System globally across Australia and the USA.

Frederic joined Noxopharm in 2017 as the Director of Pre-clinical Oncology.


Phillip Coghlan

Dr Phillip Coghlan - Director, Pharmaceutical Chemistry

Dr Phillip Coghlan joins Noxopharm having spent the past 16 years in industry regulation at the Australian Pesticides and Veterinary Medicines Authority (APVMA) where he was a Chemistry Evaluator, the Principal Pharmaceutical Chemist and most recently Director of Scientific Standards and Data Guidelines. Dr Coghlan also spent time at the Therapeutic Goods Administration (TGA) as an evaluator of prescription medicines. Dr Coghlan has a strong scientific background in biochemistry (BAppSc, Swinburne), organic chemistry (PhD, ANU) and early stage drug development (CSIRO) which he will use to help direct manufacture of Active Pharmaceutical Ingredients and Finished Drug Products. Dr Coghlan brings a wealth of knowledge and understanding of pharmaceutical chemistry and manufacture assessment and regulation to the role.